內衣品牌龍頭愛慕股份(603511.SH)首日上市漲停
格隆匯5月31日丨老牌內衣公司愛慕股份今日正式登陸上交所主板,目前股價漲44%報30.23元,達最高漲幅上限,市值121億元。愛慕股份成為繼都市麗人、匯潔股份和安莉芳控股之後的第四家中國內衣品牌上市公司。招股書顯示,2018年-2020年公司營收分別為31.18億元、33.17億元、33.62億元,呈穩定增長趨勢。但同期的營業利潤卻有下滑,從5.21億元下降到5.14億元,2019年甚至為3.99億元。招股説明書解釋,公司在報吿期內持續加強了市場推廣,因而使公司的期間費用水平整體增加。此外,公司的產品單價也有減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.